Colinz Laboratories Posts Profit Growth Despite Revenue Dip in FY26

Colinz Laboratories Ltd reported its audited financial results for the fiscal year ended March 31, 2026. The company posted a profit of ₹51.45 lakh on revenue of ₹613.61 lakh. This profit represents a modest increase from ₹49.66 lakh in the prior fiscal year. However, revenue declined from ₹652.77 lakh in FY25.

The fourth quarter (Q4 FY26) showed stronger performance, with revenue climbing to ₹174.79 lakh from ₹145.14 lakh in the same period last year. Q4 profit also increased to ₹17.12 lakh from ₹15.04 lakh year-on-year.

Colinz Laboratories' Board of Directors approved the audited financial results. Vora & Associates, the statutory auditors, issued an unmodified opinion, confirming the financial statements present a fair view. The increase in profit despite the revenue dip points to effective cost management and improved operational efficiencies throughout FY26.

Investors may note a significant drop in Total Comprehensive Income for Q4 FY26, which stood at ₹0.33 lakh compared to ₹19.57 lakh in Q4 FY25. While auditors issued an unmodified opinion on the financial statements, clarification on this variance could be sought.

Colinz Laboratories saw its revenue decline by 5.9% year-on-year in FY26, while profit grew by 3.6%. In comparison, Lasa Supergenerics Ltd, an API-focused peer, reported FY25 revenue of approximately ₹217 crore and profit of about ₹12 crore. Venus Remedies Ltd, another listed pharmaceutical firm, posted FY25 revenue of around ₹241 crore and profit of approximately ₹17 crore.

Looking ahead, investors will likely seek management commentary on the drivers behind the revenue decline and the strategies employed for profit improvement. Guidance for FY27 performance, potential strategic initiatives to boost top-line growth, and further clarification on the Q4 Total Comprehensive Income variance will also be key areas of focus.